Low frequency of skin reactions in a cohort of patients on raltegravir

HIV, antiretroviral therapy, safetySir,In the last 25 years, highly active antiretroviral therapy hasbeen continuously improving the life expectation and qualityof HIV-infected people. As new drugs were more effectiveand adverse events less frequent and severe, HIV infectionturned into a chronic disease. Recently licensed drugs, suchas raltegravir and darunavir, are characterized by high efcacyand tolerability. However, on 2 November 2011, updates tothe Isentress (raltegravir) package insert were approved bythe FDA to include a new warning, subsequent to the post-marketing experience.